Temsirolimus

Generic Name: Temsirolimus

Brand Names: Torisel

Drug Type: Small Molecule

Chemical Formula: C_₅₆H_₈₇NO_₁₆

CAS Number: 162635-04-3

Unique Ingredient Identifier: 624KN6GM2T

Background: Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.

Indication: For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.

Associated Conditions: Advanced Renal Cell Carcinoma

Associated Therapies: -

Clinical Trials

Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery

Phase 1

Completed

Conditions: Adult Solid Neoplasm

Interventions: Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Temsirolimus
Drug: Tivantinib

First Posted Date: 2012-06-21

Last Posted Date: 2015-10-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 11

Registration Number: NCT01625156

Locations: 🇺🇸
Wisconsin Clinical Cancer Center, Milwaukee, Wisconsin, United States
🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma

Phase 2

Completed

Conditions: Childhood Alveolar Soft Part Sarcoma
Childhood Liposarcoma
Childhood Malignant Peripheral Nerve Sheath Tumor
Childhood Synovial Sarcoma
Previously Treated Childhood Rhabdomyosarcoma
Childhood Angiosarcoma
Rhabdomyosarcoma
Childhood Epithelioid Sarcoma
Childhood Fibrosarcoma
Childhood Leiomyosarcoma

Interventions: Biological: Cixutumumab
Other: Laboratory Biomarker Analysis
Drug: Temsirolimus

First Posted Date: 2012-06-08

Last Posted Date: 2018-12-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 46

Registration Number: NCT01614795

Locations: 🇺🇸
Stony Brook University Medical Center, Stony Brook, New York, United States
🇺🇸
Children's Hospital Medical Center of Akron, Akron, Ohio, United States
🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States

and more 73 locations

A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

Phase 1

Completed

Conditions: Lymphoblastic Leukemia, Acute, Childhood
Peripheral T-cell Lymphoma
Lymphoblastic Lymphoma

Interventions: Drug: Temsirolimus
Drug: Etoposide
Drug: Cyclophosphamide
Drug: Methotrexate
Drug: Hydrocortisone
Drug: Cytarabine

First Posted Date: 2012-06-07

Last Posted Date: 2023-07-27

Lead Sponsor: Therapeutic Advances in Childhood Leukemia Consortium

Target Recruit Count: 16

Registration Number: NCT01614197

Locations: 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, United States
🇺🇸
Lurie Children's Hospital, Chicago, Illinois, United States

and more 29 locations

Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic Leukemia

Phase 2

Completed

Conditions: Acute Myeloblastic Leukemia

Interventions: Drug: sodium chloride solution 0.9%
Drug: temsirolimus

First Posted Date: 2012-06-04

Last Posted Date: 2023-05-24

Lead Sponsor: Goethe University

Target Recruit Count: 33

Registration Number: NCT01611116

Locations: 🇩🇪
Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany
🇩🇪
University Hospital Dresden, Dresden, Germany
🇩🇪
University Hospital Erlangen, Erlangen, Germany

and more 2 locations

Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer

Phase 1

Completed

Conditions: Advanced Cancer
Solid Tumor

Interventions: Drug: Vemurafenib
Drug: Everolimus
Drug: Temsirolimus

First Posted Date: 2012-05-10

Last Posted Date: 2020-06-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 27

Registration Number: NCT01596140

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Temsirolimus as Second-line Therapy in HCC

Phase 2

Conditions: Unresectable or Metastatic Hepatocellular Carcinoma

First Posted Date: 2012-03-30

Last Posted Date: 2012-12-17

Lead Sponsor: University of Tennessee Cancer Institute

Target Recruit Count: 25

Registration Number: NCT01567930

Locations: 🇺🇸
Boston Baskin Cancer Foundation, Memphis, Tennessee, United States

Bevacizumab and Temsirolimus Alone or in Combination with Valproic Acid or Cetuximab in Treating Patients with Advanced or Metastatic Malignancy or Other Benign Disease

Phase 1

Active, not recruiting

Conditions: Advanced Malignant Neoplasm
Castleman Disease
Digestive System Carcinoma
Erdheim-Chester Disease
Lip and Oral Cavity Carcinoma
Lymphangioleiomyomatosis
Malignant Endocrine Neoplasm
Malignant Female Reproductive System Neoplasm
Malignant Male Reproductive System Neoplasm
Malignant Neoplasm

Interventions: Biological: Bevacizumab
Biological: Cetuximab
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Valproic Acid
Drug: Temsirolimus

First Posted Date: 2012-03-13

Last Posted Date: 2024-10-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 155

Registration Number: NCT01552434

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Recurrent Uterine Corpus Sarcoma
Stage IIIB Uterine Sarcoma
Adult Solid Neoplasm
Lung Carcinoid Tumor
Stage IVA Uterine Sarcoma
Stage IVB Uterine Sarcoma
Recurrent Renal Cell Carcinoma
Stage IV Renal Cell Cancer
Stage III Renal Cell Cancer
Stage IIIC Uterine Sarcoma

Interventions: Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Temsirolimus
Biological: Trebananib

First Posted Date: 2012-03-08

Last Posted Date: 2015-10-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT01548482

Locations: 🇨🇦
BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma

Phase 1

Completed

Conditions: B-cell Lymphoma Refractory

Interventions: Drug: Inotuzumab Ozogamicin
Drug: Temsirolimus

First Posted Date: 2012-02-20

Last Posted Date: 2016-06-07

Lead Sponsor: Cristiana Sessa

Target Recruit Count: 25

Registration Number: NCT01535989

Locations: 🇨🇭
Oncology Institute of Southern Switzerland, Bellinzona, Ticino, Switzerland
🇨🇭
InselSpital, Universitätsspital Bern, Bern, Switzerland
🇨🇭
Kantonsspital St.Gallen, San Gallen, Switzerland

Temsirolimus in Combination with Metformin in Patients with Advanced Cancers

Phase 1

Active, not recruiting

Conditions: Advanced Cancers

Interventions: Drug: Temsirolimus
Drug: Metformin

First Posted Date: 2012-02-09

Last Posted Date: 2024-11-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 87

Registration Number: NCT01529593

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy